December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

20.30 +0.08 (+0.40%)
Delayed Quote Updated: 9:40 AM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Anika Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Anika (ANIK) Q2 2026 Earnings Call Transcript ↗
Revenue hit $32.6 million with record commercial channel sales and expanded margins. 
Via The Motley Fool
Topics Earnings
News headline image
Anika Therapeutics Q2 Earnings Call Highlights ↗
Anika Therapeutics (NASDAQ:ANIK) reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and... 
Via MarketBeat
Topics Earnings
Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Anika (ANIK) Q1 2026 Earnings Transcript ↗
Anika (ANIK) Q1 2026 Earnings Transcript 
Via The Motley Fool
Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat ↗
Via Chartmill
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally ↗
Via Chartmill
Topics Earnings
News headline image
Anika (ANIK) Q2 2025 Earnings Call Transcript ↗
Anika (ANIK) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Anika (ANIK) Q4 2025 Earnings Call Transcript ↗
Anika (ANIK) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting... 
Via MarketMinute
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
What's Next: Anika Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Anika (ANIK) Q3 2025 Earnings Call Transcript ↗
Anika (ANIK) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Anika Therapeutics Inc (NASDAQ:ANIK) Reports Q3 2025 Earnings Beat and Positive Regulatory Milestone ↗
Anika Therapeutics (ANIK) beat Q3 2025 earnings estimates with a profit of $0.04 per share, driving its stock up over 10% despite a slight revenue miss. 
Via Chartmill
Topics Earnings
News headline image
Anika (ANIK) Q2 Revenue Beats by 4% ↗
Via The Motley Fool
Topics Economy
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Reports Mixed Q2 2025 Results with Revenue Beat but EPS Miss, Shares Drop 9% in Pre-Market ↗
Anika Therapeutics reported mixed Q2 2025 results, with revenue beating estimates but EPS missing. Shares fell 9% amid Hyalofast trial concerns despite strong regenerative solutions growth. 
Via Chartmill
News headline image
Anika Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Outlook For Anika Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of Anika Therapeutics's Earnings Potential ↗
 
Via Benzinga
News headline image
Microsoft To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert ↗
U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print. 
Via Benzinga
Topics Economy
News headline image
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 12, 2025 ↗
 
Via Benzinga
News headline image
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
ANIK stock results show that Anika Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ANIK stock results show that Anika Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 13, 2024 ↗
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.